文献速递眼底病与葡萄膜炎

PDE6A相关视网膜色素变性的视网膜下基因补充治疗的安全性与视力结局:一项非随机对照试验

Safety and vision outcomes of subretinal gene supplementation therapy in PDE6A-associated retinitis pigmentosa: a non-randomised controlled trial.
PubMed 文献 · Br J Ophthalmol · 2026-01-22

这项开放标签、非随机对照I/IIa期试验纳入9例双等位基因PDE6A变异患者,单次视网膜下注射AAV8.hPDE6A,剂量为1.0×10¹⁰(n=6)或5.0×10¹⁰(n=3)总载体基因组。1年内未发生全身不良事件,但出现持续性不良事件包括视网膜中央变薄和视力下降,视力功能指标变化无统计学意义,未改善视功能。

要点

  • 9例PDE6A相关视网膜色素变性患者接受单次视网膜下注射AAV8.hPDE6A,剂量为1.0×10¹⁰(n=6)或5.0×10¹⁰(n=3)总载体基因组。
  • 未发生全身 adverse 事件,多数眼部事件未经治疗缓解;持续性事件包括周边小萎缩区(n=2)、色觉障碍(n=3)、白内障(n=1)、视网膜中央轻度变薄(n=5)和中度视力下降(n=2,每个剂量组各1例)。
  • 最佳矫正视力、全视野刺激阈值等视功能指标变化无统计学意义,治疗眼视网膜敏感性呈恶化趋势。

核心结论

  • 视网膜下注射AAV8.hPDE6A基因治疗1年内未改善视功能,并带来视网膜中央变薄和视力下降等风险,与临床前模型确立的安全性和有效性特征相反。

研究设计与样本

  • 开放标签、非随机对照I/IIa期试验,纳入9例双等位基因PDE6A变异患者,单次视网膜下注射AAV8.hPDE6A,剂量为1.0×10¹⁰(n=6)或5.0×10¹⁰(n=3)总载体基因组。

主要发现

  • 患者平均年龄40.1岁,基线最佳矫正视力范围为40至82个字母(0.9-0.1 logMAR)。
  • 未发生全身不良事件,多数眼部事件未经治疗缓解;持续性不良事件包括周边小萎缩区(n=2)、色觉障碍(n=3)、白内障(n=1)、视网膜中央轻度变薄(n=5)和中度视力下降(n=2,每个剂量组各1例)。
  • 最佳矫正视力、全视野刺激阈值及其他视功能指标变化无统计学意义,治疗眼视网膜敏感性呈恶化趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PDE6A-associated retinitis pigmentosa (RP) is a rare inherited retinal disease leading to severe vision loss and blindness, with no available treatment. This study assessed the safety and vision outcomes of a gene therapy using an adeno-associated virus (AAV) vector encoding PDE6A (AAV8.hPDE6A). METHODS: In an open-label, non-randomised controlled phase I/IIa trial, nine patients with biallelic PDE6A variants received a single subretinal injection of AAV8.hPDE6A. Doses were either 1.0×10¹⁰ (n=6) or 5.0×10¹⁰ (n=3) total vector genomes. Safety was the primary endpoint, assessed via clinical examinations, laboratory analyses and optical coherence tomography imaging. Secondary outcomes included changes in visual function, such as best corrected visual acuity (BCVA), contrast sensitivity, colour perception, dark adaptation thresholds, visual fields, patient-reported outcomes and chromatic pupil campimetry over 1 year. RESULTS: The mean patient age was 40.1 years, with baseline BCVA ranging from 40 to 82 letters (0.9-0.1 logMAR). No systemic adverse events occurred, and most ocular events resolved without treatment. Persistent adverse events included small peripheral atrophic areas (n=2), disturbed colour discrimination (n=3), cataract (n=1), slight central retinal thinning (n=5) and moderate visual acuity loss (n=2, 1 in each dose group). BCVA, full-field stimulus thresholds and other visual function measures showed statistically non-significant changes, with a trend towards worsening of retinal sensitivity in the treated eyes. CONCLUSION: Subretinal gene therapy with AAV8.hPDE6A did not improve visual function over 1 year and posed risks, including central retinal thinning and visual acuity decline. This is in contrast to the safety and efficacy profile established in preclinical models.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Reichel FF, Fischer MD, Stingl K, et al. Safety and vision outcomes of subretinal gene supplementation therapy in PDE6A-associated retinitis pigmentosa: a non-randomised controlled trial. Br J Ophthalmol. 2026. PMID: 40825661. doi:10.1136/bjo-2024-326480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。